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Selection of Tumorigenic Melanoma Cells Using
ALDH
Jim B. Boonyaratanakornkit1,2,8, Lili Yue2,8, Lauren R. Strachan1,2, Kenneth J. Scalapino3, Philip E. LeBoit4,
Ying Lu5, Stanley P. Leong6, Janellen E. Smith7 and Ruby Ghadially1,2
Despite increasing knowledge regarding melanoma-initiating cells (MICs), questions persist regarding the
number and phenotypic nature of cells with tumor-generating capability. Evidence for a phenotypically distinct
human MIC has been found in NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice.
However, a phenotypically distinct human MIC was not found in the NOD/SCIDIl2rg/ (NSG) mouse model.
The demonstration of a distinct population of human melanoma cells responsible for tumorigenesis and tumor
cell self-renewal would provide an important target for new melanoma therapies. In this study, we show a 100-
fold range in MIC frequency in human melanoma (1 in 18,000 to 1 in 1,851,000 cells) in the NOD/SCID mouse. In
this model, human melanoma cells with high aldehyde dehydrogenase (ALDH) activity were enriched 16.8-fold
in tumorigenic cells over unfractionated (UNF) cells, such that 1 in 21,000 cells was a MIC. In the NSG mouse,
the ALDH expressing cell population was enriched 100-fold in tumorigenic cells over UNF cells, such that one in
four cells was a MIC. Xenograft melanomas that developed from ALDHþ cells displayed robust self-renewal,
whereas those from ALDH cells showed minimal self-renewal in vitro. Thus, ALDHþ melanoma cells have
enhanced tumorigenicity over ALDH cells and superior self-renewal ability.
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INTRODUCTION
According to the cancer stem cell hypothesis, most cancer
cells are unable to proliferate extensively and only a small
phenotypically distinct subset of cells can consistently
proliferate and form new tumors upon transplantation (Reya
et al., 2001). The role of cancer stem cells in maintaining
myeloid leukemia (Lapidot et al., 1994) and several solid
cancers (Hermann et al., 2007; O’Brien et al., 2007; Prince
et al., 2007; Ricci-Vitiani et al., 2007) has been established
through transplantation studies. Previous studies have also
provided evidence for a phenotypically distinct tumor-
initiating cell in melanoma. Melanoma cells propagated as
non-adherent spheres expressed higher levels of CD20 than
adherent cells, and were more tumorigenic than adherent
cells when injected into mice (Fang et al., 2005). Grichnik
et al. (2006) showed that small Hoescht dye-excluding
melanoma cells shared many properties with normal stem
cells, including slower proliferation and greater expansion in
culture. Furthermore 100,000 CD133þ melanoma cells
formed xenograft tumors, whereas 100,000 CD133 cells
did not (Monzani et al., 2007) and ABCB5 expressing
melanoma cells were enriched for cells with tumorigenic
capacity 6.8-fold over unfractionated (UNF) cells such that 1
in 158,170 cells was a melanoma-initiating cell (MIC)
(Schatton et al., 2008). Finally, using a murine melanoma
model and injection into nude mice, melanoma formation
occurred after every injection of individual CD34þp75 cell,
but only rarely with CD34p75þ cells (Held et al., 2010).
Although the above work supports the existence of a
phenotypically distinct MIC, when tumorigenic melanoma
cells were examined in the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mouse, the tumorigenic cell was a frequent cell and no
specific phenotype was found (Quintana et al., 2008).
One approach to finding markers of tumorigenic cells is to
focus on conserved progenitor cell functions (Ginestier et al.,
2007a). Using this approach we selected aldehyde dehydro-
genase (ALDH) activity as a candidate marker of MICs. ALDH
is involved in retinoic acid metabolism and confers a
protective function against xenobiotics (Vasiliou et al.,
2000). ALDH activity has been identified as a stem cell
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marker in normal human hematopoietic cells (Hess et al.,
2004) and in multiple tumors (Storms et al., 1999; Seigel
et al., 2005; Cheung et al., 2007; Ginestier et al., 2007a, b).
CD133 was also examined as a possible marker of MICs.
CD133 is a cell surface glycoprotein (prominin-1), whose
function has not been established. CD133 marks stem cells in
normal (Hess et al., 2006) and cancerous tissues (Singh et al.,
2003; Hermann et al., 2007; O’Brien et al., 2007; Ricci-
Vitiani et al., 2007).
In this study, limiting dilution analyses in NOD/SCID
(non-obese diabetic/severe combined immunodeficiency)
mice revealed a 100-fold variation in MIC frequency in
melanomas from different patients. In the NOD/SCID mouse,
the ALDHhiSSClo population of human melanoma cells was
enriched in MICs 16.8-fold over UNF cells. In the NSG
mouse, ALDHþ cells were enriched in MICs 100-fold over
the UNF cell population (such that one in four cells was a
MIC) and tumors that developed from ALDHþ cells showed
superior self-renewal in vitro over the occasional tumors that
developed from ALDH cells. These studies provide evi-
dence for a phenotypically distinct tumorigenic cell in
melanoma that has superior self-renewal ability.
RESULTS
The frequency of human melanoma initiating cells in
NOD/SCID mice
To determine the range in MIC frequency in melanomas from
different patients, cell suspensions were xenografted sub-
cutaneously into NOD/SCID mice at various doses and tumor
growth was followed over time (Figure 1a). Only one patient
sample failed to grow after transplantation. Xenografted
tumors recapitulated the original patient tumor with similar
histopathologic features (Figure 1b). The frequency of MICs in
freshly obtained specimens from individual patients showed a
100-fold range, from 1 in 18,000 to 1 in 1,851,000 cells
(Table 1). Thus, in all patients only a fraction of tumor cells
initiated further tumor growth in NOD/SCID mice, and the
size of the fraction varied greatly.
The time to first palpability was different in xenografts
from different patients. In order to use data from all cell
doses, a Cox regression model using cell doses as strata was
used to associate time to palpability with MIC frequency. The
hazards ratio for shortened time to palpability was 1.24 per 1
MIC increase in 150,000 cells (95% confidence interval (CI)
1.08 to 1.142, P¼0.017). Thus, there was a significant
association between increased MIC frequency and decreased
time to first palpability (Figure 1c).
For the 13 patients examined (Table 1, Supplementary
Table S1 online), there was an inverse correlation between
MIC frequency and metastasis-free survival (time between
diagnosis of the primary melanoma and diagnosis of
metastatic melanoma). Spearman’s correlation coefficient
was –0.6035 (P¼ 0.038), such that the higher the MIC
frequency, the shorter the time to metastasis (Supplementary
Figure S1 online).
In general, the melanoma samples effaced the lymph node
and were sheets of melanoma cells microscopically. Cell
counts under the microscope excluded lymphocytes (by size
and morphology), which constituted 5–15% of cells. To
examine whether it was likely that proportions of contaminat-
ing cells contributed to the results obtained above by affecting
xenograft growth, we studied the number of CD45þ and
CD31þ human cells in primary lesions and xenografts. For PM
41 (MIC frequency 1 in 18,000), PM 28 (1 in 20,000), PM 37 (1
in 161,000) PM 22 (1 in 710,000), and PM 47 (1 in
42,000,000), there was no evidence for a correlation between
the number of contaminating cells (by immunoperoxidase for
human-specific CD45 and CD31 and MIC frequency (Supple-
mentary Figure S2 online). In the corresponding xenografts,
neither CD45þ nor CD31þ human cells were found
(Supplementary Figure S3 online). Thus, these data do not
provide evidence that contaminating cells contributed signifi-
cantly to the 100-fold difference in MIC frequency.
The population of human melanoma cells with high ALDH
activity is enriched in MICs in NOD/SCID mice
We next determined whether cells marked by high ALDH
activity (ALDHhiSSClo) were tumorigenic cells. Freshly
obtained melanoma cells were sorted for ALDH acti-
vity using Aldefluor (Stemco Biomedical, Durham, NC)
(Figure 2a). Diethylaminobenzaldehyde, an ALDH inhibitor,
was the negative control. The selected ALDHhiSSClo popula-
tion was 2% of live cells (Figure 2a). Dead cells were
excluded using 7-aminoactinomycin D. Lymphocytes formed
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Figure 1. Xenograft growth in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Cells from fresh human metastatic melanoma were
injected subcutaneously into NOD/SCID mice. (a) Tumors were excised for pathological confirmation of melanoma and serial transplantation. (b) Primary
melanoma in patient (above) and xenograft in mouse (below) (ID 42) showing similar histopathological features (bar¼ 10 mm). (c) Time to first palpability of the
xenograft is significantly longer for tumors with low melanoma-initiating cell (MIC) frequency. Linear regression was used to plot a trend line (P¼ 0.017).
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Table 1. Characteristics of melanomas from patients with lymph node metastases (in NOD/SCID mice)
Limiting dilution analysis Growth in vivo
Patient
ID, age, sex No. of cells Response ratio MIC frequency (95% CI)
Time to metastasis
(months)
Xenograft latency
(weeks)
41, 60 years, F 800,000 2/2 1 in 18,000 (6,000–56,000) 23 6
400,000 2/2
100,000 3/3
25,000 3/4
28, 38 years, M 1,600,000 2/2 1 in 20,000 (6,000–64,000) 1** 5
800,000 4/4
400,000 4/4
100,000 6/6
25,000 2/3
42, 63 years, F 1,600,000 3/3 1 in 61,000 (28,000–135,000) 24 7
800,000 6/6
400,000 6/6
100,000 6/6
25,000 0/6
29, 60 years, F 1,600,000 2/2 1 in 99,000 (39,000–249, 000) 6 5
800,000 5/5
400,000 4/4
100,000 3/4
25,000 0/4
36, 60 years, F 1,600,000 3/3 1 in 100,000 (47,000–214,000) 1** 5
800,000 6/6
400,000 6/6
100,000 3/6
25,000 2/6
25, 63 years, M 1,300,000 1/1 1 in 113,000 (29,000–432,000) 3 8
800,000 1/1
500,000 1/1
400,000 2/2
100,000 1/2
23, 87 years, M 1,600,000 1/1 1 in 113,000 (62,000–204,000) 4 6
800,000 8/8
400,000 13/14
100,000 7/9
25,000 0/2
37, 54 years, M 1,600,000 3/3 1 in 161,000 (71,000–369,000) 7 13
800,000 6/6
400,000 5/6
100,000 2/2
25,000 0/2
24, 79 years, F 1,700,000 1/1 1 in 263,000 (134,000–517,000) 144 4
800,000 4/5
400,000 5/5
Table 1 continued on the following page
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a smaller, less complex population than the melanoma
cells and could be excluded on the forward scatter/side
scatter (FSC/SSC) plot. Remaining hematopoietic cells were
excluded using CD45 (Figure 2a), such that the ALDHþ
population was found to be over 99.5% CD45CD31, and
the ALDH population was over 95% CD45CD31 (not
shown). ALDHhiSSClo cells from a melanoma cell line (WM-
266-4) were enriched for MICs 5.7-fold over UNF cells so
that 1 in 65 cells (95% CI 1 in 43 to 1 in 97 cells) versus 1 in
370 UNF cells (95% CI 1 in 190 to 1 in 710) was a MIC
(Table 2a). ALDHhiSSClo cells from freshly collected patient
melanomas (n¼3) or human melanomas grown for one
passage in the NOD/SCID mouse (n¼ 6) were also enriched
in MICs 16.8-fold, such that 1 in 21,000 cells (95% CI 1 in
14,000 to 1 in 30,000) versus 1 in 353,000 UNF cells (95%
CI 1 in 246,000 to 1 in 507,000) was a MIC (Table 2b).
Xenograft melanomas that developed from ALDHhiSSClo cells
contained both ALDHhi and ALDH cells by FACS (Figure
2b). Furthermore, 5,000 ALDHhiSSClo cells secondarily
transplanted into NOD/SCID mice could once again produce
a xenograft melanoma. These studies provide evidence that
the ALDHhiSSClo population contains the tumorigenic cells,
can self-renew, and produce a range of progeny in the NOD/
SCID mouse.
The population of human melanoma cells that expresses
CD133 is enriched in MICs in NOD/SCID mice
The CD133-positive population was examined for MIC
enrichment. By flow cytometry, CD133þ cells constituted
0.01–0.2% of cells (Figure 2c) and 2.9–29% of CD133þ were
ALDHhi. AutoMACS was used to isolate CD133þ melanoma
cells for limiting dilution analysis from three fresh melanoma
samples. CD133þ cells were enriched for MICs 2.9-fold
over UNF cells, such that 1 in 43,000 cells (95% CI 1 in
20,000 to 1 in 90,000) was a MIC (Table 2c). CD133 cells in
large doses (800,000) contained MICs in 12 out of 12
samples, suggesting that there may be a distinct population
of MICs that is CD133. This is reminiscent of findings
in glioblastoma (Beier et al., 2007). Given the lesser
enrichment with CD133 versus ALDH, we did not pursue
this marker further.
Serial transplantation and MIC frequency in NOD/SCID mice
To determine whether serial transplantation altered MIC
frequency, we transplanted tumors with a range of MIC
frequencies through six serial transplantations. After 2–3
transplantations, tumors characterized by low MIC frequency
achieved high MIC frequency and had shorter time to first
palpability (Figure 2d). Tumors characterized by high MIC
frequency maintained high MIC frequency through serial
transplantations, and exhibited decreased time to palpability
after 2–3 serial transplantations (Figure 2d).
The population of human melanoma cells that expresses
ALDH is enriched for MICs in NSG mice
We then examined whether ALDH-expressing cells were the
tumorigenic cells in NSG mice. Although previous hemato-
poietic studies used ALDHhiSSClo populations, more recent
studies in solid tumors used ALDHþ cells. We examined
both 2% ALDHhiSSClo cells and ALDHþ cells (ALDHþ cells
comprised 0.46–5.8% of melanoma cells) and no difference
in either MIC frequency or in time to first palpability in the
NSG mouse was detected (Supplementary Tables S2 and S3
online). Accordingly, in subsequent studies, we used the
Table 1. Continued
Limiting dilution analysis Growth in vivo
Patient
ID, age, sex No. of cells Response ratio MIC frequency (95% CI)
Time to metastasis
(months)
Xenograft latency
(weeks)
100,000 3/7
25,000 0/7
52, 46 years, F 400,000 0/1 1 in 649,000 (80,000–5,300,000) 300 19
100,000 1/3
22, 42 years, M 3,200,000 1/1 1 in 710,000 (368,000–1,370,000) 32 10
800,000 5/7
400,000 3/7
100,000 1/9
25,000 0/8
19, 31 years, M 1,700,000 1/1 1 in 1,851,000 (484,000–7,072,000) 69 13
400,000 1/6
100,000 0/6
25,000 0/6
6,250 0/6
Abbreviations: CI, confidence interval; F, female; M, male; MIC, melanoma-initiating cell; NOD/SCID, non-obese diabetic/severe combined
immunodeficiency.
**Metastases present at time of initial diagnosis.
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entire ALDHþ cell population. ALDHþ human melanoma
cells were enriched in MICs such that 1 in 4 (95% CI 3–5)
ALDHþ cells versus 1 in 418 (95% CI 302–579) UNF cells
(P¼0.0001), or 1 in 601 (95% CI 463–779) ALDH cells
(P¼0.0001) was capable of tumorigenesis (Figure 3a).
Median time to first palpability was significantly shorter for
tumors derived from ALDHþ cells versus tumors from equal
numbers of ALDH or UNF cells (Figure 3b and Supplemen-
tary Figure S4 online). These studies demonstrate that
ALDHþ cells were enriched in tumorigenic cells compared
with ALDH or UNF cells and that tumors from ALDHþ cells
had shorter time to first palpability than tumors from UNF or
ALDH cells.
An increased MIC frequency might be found if all cells
were equally tumorigenic, but the proliferation of the cells in
one tumor versus another was more rapid. To address this
possibility, we studied tumors from Figure 3 and assessed the
frequency of ALDHþ cells by FACS, MIC frequency, mitotic
index, Ki-67 expression, and the weeks to first palpability (an
in vivo reflection of doubling time) (Figure 4). In these cases,
the tumor with the highest proportion of ALDHþ cells in the
tumor by FACS had the highest MIC frequency. There was no
significant difference in mitotic index between the tumors, or
in Ki-67 staining. For UNF cells, the time to first palpability
was longest for the tumor with the lowest percentage of
ALDHþ cells. However, when ALDHþ cells only were
injected, no statistical difference was detected in the median
weeks to first palpability. Thus, at least for the tumors
examined, no correlation was found between the mitotic
index and MIC frequency.
To determine whether ALDHþ melanoma cells were
capable of ongoing self-renewal, whereas ALDH cells were
not, serial transplantation in vitro was performed. Xenografts
that developed from ALDHþ or ALDHhiSSClo melanoma
cells contained similar proportions of ALDHþ cells to the
tumors that developed from UNF cell injections (Figure 3c),
whereas tumors that developed from ALDH cells contained
small numbers of ALDHþ cells. Xenografts (from Figure 3)
were transplanted in vitro to examine self-renewal ability
(20,000 cells per well, in 24-well plates). Cells from
xenografts that developed from ALDHþ , ALDHhiSSClo, and
UNF cells grew well in culture, whereas the xenografts that
developed from ALDH cells did not grow or grew poorly
(Figure 3d and Supplementary Figure S5 online). Thus,
xenografts from ALDHþ melanoma cells displayed superior
self-renewal to xenografts from ALDH cells.
FACS sorting for ALDH cell populations with Aldefluor
ALDHþ cells were present in the xenografts that developed
from ALDH cells, consistent with either, ALDHþ cells
present in the ALDH cells selected by FACS, or ALDH cells
producing or becoming ALDHþ cells (see Figure 3c). To
determine if ALDHþ cells persist in FACS-sorted ALDH
populations, we performed double and triple sorts of FACS-
sorted ALDH cells. When ALDH cells were double-sorted
0.2–1% of cells that were in the ALDH gate on the first sort
were in the ALDHþ gate on the second sort, and after triple
sorting, 0–0.4% of previously ALDH cells were found in the
ALDHþ gate (n¼4). FACS sorting produces highly purified
populations of cells, yet is clearly unable to eliminate all
ALDHþ cells.
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Figure 2. Expression of aldehyde dehydrogenase (ALDH) and CD133 in
human melanoma. (a) Cells from individual patients were sorted by flow
cytometry. ALDH high (ALDHhi), non-complex (SSClo) cells, comprising 2% of
the total live population, were isolated. CD45þ hematopoietic cells were
excluded. (b) Flow cytometry of a non-obese diabetic/severe combined
immunodeficiency (NOD/SCID) xenograft tumor derived from 5,000
ALDHhiSSClo cells, showing cellular heterogeneity. (c) CD133þ cells comprise
0.01–0.2% of the total population in our samples. (d) Serially transplanted
tumors. Melanoma-initiating cell (MIC) frequency for tumors with lower initial
MIC frequency increased with successive transplantations and approached that
of tumors with high initial MIC frequency by the third serial transplant. With
successive serial transplants, tumors were palpable earlier. *MIC frequency at
first passage o1 in 1 million. SSC-A, side scatter area.
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Table 2. The population of human melanoma cells with high ALDH activity is enriched in MICs
(a) ALDH: WM-2664 cell line
Number of tumors/number of injections
Cells per injection
Tumorigenic cell
frequency (95% Cl)
10,000 1,936 968 242 100 30 7.5 3
ALDHhiSSClo 8/8 12/47 10/36 0/8 1 in 65 (43–97)
ALDH 0/7 2/16 4/8 1/16 1 in 16,000 (6,880–35,000)
UNF 9/38 1 in 370 (190–710)
(b) ALDH: patient (n=3) and xenograft (n=6) melanomas
Number of tumors/number of injections
Cells per injection
Tumorigenic cell
frequency (95% Cl)
800,000 400,000 200,000 100,000 25,000 5,000
Xe1 2/4 1/4
Xe2 3/4 1/4
Xe3 4/6 2/6
Xe4 1/1 1/1
ALDHhiSSClo Xe5 2/2 1/2
Xe6 3/4 3/4
PM1 1/3 0/3
PM2 0/4 0/4
PM3 4/5 3/6
All 20/33 12/34 1 in 21,000
(14,000–30,000)
Xe3 0/5
Xe4 1/1
Xe5 0/1
ALDH Xe6 0/2 1/6
PM2 0/6
PM3 2/4
All 1/6 2/12 1/7 1 in 588,000
(217,000–1,593,000)
Xe1 1/1 3/3 0/4 0/4
Xe2 2/2 4/4 0/4 0/4
Xe3 0/2 0/2
Xe4 2/2 2/2 1/2 1/2
Xe5 1/1 1/1 1/3
UNF Xe6 2/2 2/2 0/4
PM1 1/2 2/4 2/4
PM2 2/2 3/4 2/4 0/4
PM3 1/1
All 11/14 18/23 6/25 1/14 1 in 353,000
(246,000–507,000)
(c) CD133: patient melanomas (n=5)
Number of tumors/number of injections
Cells per injection
Tumorigenic cell
frequency (95% Cl)
1,600,000 800,000 400,000 100,000 25,000 5,000
CD133+ 6/13 1/12 1 in 43,000
(20,000–90,000)
CD133 12/12 —
UNF 8/8 7/8 6/8 1 in 124,000
(61,000–252,000)
Abbreviations: ALDH, aldehyde dehydrogenase; CI, confidence interval; MIC, melanoma-initiating cell; SSC, side scatter area; UNF, unfractionated.
2804 Journal of Investigative Dermatology (2010), Volume 130
JB Boonyaratanakornkit et al.
ALDH and Melanoma-Initiating Cells
Tumorigenic cell
frequencyNumber of tumors/number of injections
Xe121
5,000
2/2
2/2
2/2
2/2
2/2
2/2
2/2
2/2
2/2
2/2
5/6
2/2
1/2 1/6
1/4 1/4
4/4 4/4
2/4
2/4
UNF ALDH+ ALDHhiSSClo ALDH–
7/12
4/4
9/12
4/4
0/6 0/6
0/6
0/6
0/4
–
–
– –
–
–
–
––
– –
– –
– –
– –
–
–
–
1/6
3/6
4/18
0/4
6/6 6/6
4/6
10/18
2/4
6/6
6/6
13/18
3/4
6/6
6/6 6/6
100
3/6 2/8
1 in 4 (3–5)
(463–779)
(302–579)
(72–283)
(270–812)
(2–7)1 in 4
1 in 601
1 in 418
1 in 142
1 in 469
2/6
6/6
10/20
6/6
6/6
15/18
6/6
6/6
6/6
6/6
18/18 18/18
4/4 4/4 4/4 0/4
1,000
Cells per injection
Cells per injection
10 1
Xe122
Xe135
Xe All
Xe121
Xe121
Xe122
Xe122
Xe135
Xe135
Xe AII
Xe AII
PM142
PM142
5,000
Xe121
Xe121
Xe121
5.3 6.1 8.5 8
13.9
7.3
19.1
10.9
6.8
14.7
6.3
8.7
5.9 5.9
5.3
10.2
Xe122
Xe122
Xe122
PM142
PM142
PM142
Si
de
 s
ca
tte
r
Xe141
Xe122
ALDH-FITC
256 K
192 K
128 K
64 K
0
1.7 1.9 2.5 1.9 1.2
0.42.42.41.91.7
103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
256 K
192 K
128 K
64 K
0 103 104 105
ALDH+
ALDH–
UNF
Xe135
Xe135
Xe135
1,000 100 10 1
10.1
15.4
8.8
NG
NGNGNG
23.915.9
11.3
23.710.7
11.8
13.9
821.1
13.1 10.1 12.1
12.4
11.3
19.7
8.8
9.3
13.2
6.8
7.8
11.2
Primary UNF ALDH+ ALDHhi SSClo ALDH–
8.2
9.3
12.2
12.3
NG
NG
NGNG
Median weeks to first palpability
ALDH+
ALDH–
UNF
PM142
SE
Figure 3. The population of human melanoma cells with high aldehyde dehydrogenase (ALDH) activity is enriched in melanoma-initiating cells (MICs) in
non-obese diabetic Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. (a) Flow cytometry was used to select ALDHþ , ALDH, and unfractionated (UNF) cells from human
melanoma xenografts. CD45, CD31, and Ter119 were used to exclude murine cells. 7-Aminoactinomycin D was used to exclude dead cells. A range of cell doses
was injected into NSG mice. After 32 weeks, limiting dilution analysis was used to assess MIC frequency. (b) The median weeks until tumors were first palpable was
recorded for xenografts derived from ALDHþ , ALDH, and UNF cell populations. (c) Xenograft melanomas that had developed from UNF, ALDHþ , ALDHhiSSClo,
or ALDH cell populations were harvested, and FACS analysis was used to determine the frequency of ALDHþ cells. (d) Xenograft melanomas that developed from UNF,
ALDHþ , ALDHhiSSClo, or ALDH cell populations were harvested, dissociated, and plated at 20,000 cells per well into 24-well plates (2cm2) for 14 days, after which
wells were stained with toluidine blue. NG, no growth.
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Immunostaining for ALDH
We then performed immunoperoxidase studies to detect
differences in ALDH expression in fresh human melanomas
(Supplementary Figure S6 online). Eleven of 13 primary
melanomas and 11 of 14 metastatic lesions had 0–10%
ALDH-positive cells, whereas 2 of 13 primaries and 3 of 14
metastastic lesions had 50–100% positive cells. In tumors
with small numbers of ALDHþ cells (0–10%), some ALDHþ
cells had melanoma cell morphology (large aberrant nucleus)
and a nested location, whereas other cells were infiltrating
macrophages, making tumors with small numbers of ALDH-
positive cells difficult to assess. In three paired primary/
metastasis samples, we found that each of the primaries and
each of the metastases had 0–10% positive cells, and thus
there was no evidence for expansion of the ALDHþ
population in metastases over corresponding primary lesions.
DISCUSSION
Isolating tumorigenic populations of cancer cells is a first step
in identifying cells that may constitute cancer stem cells,
based on the ability for long-term self-renewal and on a
differentially expressed and stable stem cell lineage marker/
phenotype.
There was a 100-fold range in the frequency of human
melanoma cells capable of tumorigenesis in NOD/SCID
mice. Previous studies in breast cancer also showed that
while a few tumors have extensive ALDH activity (essentially
100% ALDH-positive cells), most tumors have only 0–10%
ALDH-positive cells by immunohistochemistry (Ginestier
et al., 2007a). These findings are consistent with the low
frequency of tumor-initiating cells by NOD/SCID xenotrans-
plantation in most tumors, and the wide range of frequency
between tumors.
We, similar to others, found that melanoma cells that can
produce tumor in a NOD/SCID mouse are rare (Schatton
et al., 2008). The frequency of MICs found in NSG mice in
the studies presented here is somewhat lower than that found
previously (Quintana et al., 2008). However, tumors
appeared with similar time to first palpability. The patient
samples are different and the methods may have been
somewhat different. For example, the type of Matrigel used is
not stated by Quintana et al. (2008), so that they may have
used the High Concentration Matrigel No. 354248 (whereas
we used the regular Matrigel Basement Membrane Matrix
No. 354234 (BD Biosciences, San Jose, CA).
The fact that tumors develop from ALDH cells suggests
three possibilities: ALDHþ cells are present in the ALDH
population as a result of technical limitations of FACS,
ALDH cells produce or become ALDHþ cells, or, tumors
form from ALDH cells that are part of a distinct MIC
population. We believe that the limitation of FACS-sorting is
the most likely cause of tumors that develop from ALDH
cells because; (1) ALDHþ cells were present in the ALDH
cell-derived xenografts, (2) ALDHþ cells persisted in FACS-
sorted populations of ALDH cells, and (3) while ALDHþ
cells produce tumors more rapidly than equivalent numbers
of ALDH cells, the time to first palpability for 5,000 ALDH
cells is much longer for ALDH cells from the primary tumor
containing the least ALDHþ cells (there are presumably less
contaminating ALDHþ cells in this ALDH sample, and
therefore slower tumor growth). However, this does not
eliminate the possibility that ALDH cells produce or
become ALDHþ cells. Extensive molecular studies will be
needed to determine whether ALDH can be used for
enrichment for melanoma-initiating activity without necessa-
rily supporting a cancer stem cell theory (ALDH is not a
% ALDH+
(FACS)
Xe121
Xe135
Xe122
Control (Xe121) Ki-67 (Xe121) Ki-67 (Xe122) Ki-67 (Xe135)
0.46
1.35
>1 in 156
1 in 1,650 10.9 ± 2.6 86 13.1 21.1 5.3
5.3
5.9
9.3
8.2
UNF (5,000) ALDH– (5,000) ALDH+ (5,000)
7.8
6.885
868.7 ± 3.7
10.6 ± 2.8
1 in 142
4.39
MIC frequency
(UNF)
Mitotic index
(/hpf)
% Ki-67+ Median time to first palpability for
tumors from
Figure 4. Melanoma-initiating cell (MIC) frequency and tumor proliferation. (a, b) The tumors from Figure 3a were assessed for the percentage of
ALDHþ cells by FACS, MIC frequency, mitotic rate, Ki-67 expression (cells in active cell cycle), and time (weeks) to first palpability for the xenograft
(bar¼ 10 mm). ALDH, aldehyde dehydrogenase.
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stable phenotype), or whether ALDH cells represent true
cancer stem cells with a stable phenotype.
Serial transplantation has been shown to lead to the
in vivo selection of cells that recapitulate tumors with
increased aggressiveness (Clark et al., 2000). In the studies
presented here, serial transplantation of tumors resulted in an
increased frequency of MICs as well as decreased time to first
palpability. This may be related to the altered environment,
with the niche and immune system of the NOD/SCID mouse
perhaps doing less to inhibit tumorigenesis than the original
human host.
Growth of tumors from freshly isolated cells could be
affected by the presence of non-melanoma cells. Lympho-
cytes were easily excluded from cell counts based on size.
Immunoperoxidase studies showed that CD45 and CD31
expressing human cells did not survive in the xenograft, and
staining of the human samples did not reveal a correlation
between the MIC frequency and the degree of infiltrating
human non-melanoma cells. However, the loss/absence of
non-melanoma cells could be a contributory factor to the
increased MIC frequency observed with serial transplants,
and the presence of non-melanoma cells could affect
whether or not a tumor develops.
In summary, human melanomas show a 100-fold variation
in the number of cells with tumor-initiating ability in
the NOD/SCID mouse, and tumors with high MIC frequency
have shorter time to first palpability in a xenograft model
than melanomas with low MIC frequency. Furthermore,
the population of human melanoma cells that expresses
ALDH is enriched for MICs in both the NOD/SCID
and NSG mouse models and has stem cell characteristics
of self-renewal and ability to generate heterogeneous
descendants.
MATERIALS AND METHODS
Melanoma cell preparation
Metastatic melanomas were obtained intraoperatively from patients
at the UCSF Helen Diller Cancer Center, with written, informed
patient consent, adherence to the declaration of Helsinki principle
guidelines and Committee on Human Research approval. As in most
human melanoma studies (Monzani et al., 2007; Quintana et al.,
2008; Schatton et al., 2008), metastatic melanomas were used, as
obtaining fresh primary melanomas is difficult due to the require-
ment of the entire lesion for pathological evaluation. Extraneous
tissue was trimmed and the tumor was minced and placed in 1000
collagen digestion Uml1 of Collagenase, 1300Uml1 of Hyalur-
onidase, and 200 Kunitz Uml1 DNase I (Sigma, St Louis, MO) in
Hank’s solution (Cambrex, Walkersville, MD) with 10% fetal bovine
serum (Invitrogen, Carlsbad, CA). After 90–120minutes at 37 1C, the
cell suspension was filtered (100 mm strainer, Becton Dickinson,
Mountain View, CA). Cell counts and viability were determined
using a Neubauer hemacytometer (Hausser Scientific, Horsham,
PA). Dead cells were excluded using 0.4% Trypan Blue (Sigma), and
lymphocytes by size and morphology.
Cell culture
Patient melanoma cells and the cell line WM-266-4 (from a human
metastatic melanoma in lymph node) were cultured in Eagle’s
minimum essential medium (ATCC, Manassas, VA), 10% fetal
bovine serum, and 1% antibiotic/antimycotic (Invitrogen).
Subcutaneous injection of melanoma cells
The NOD/SCID mouse and the NSG mouse (Jackson Laboratory, Bar
Harbor, ME) models were utilized. Melanoma cells were injected
subcutaneously on the dorsal surface. Cell viability was B90%.
Tumors were followed for up to 24 (NOD/SCID) or 36 (NSG) weeks.
After killing, injection sites were excised, and histological examina-
tion determined the presence of tumor. Tumors were excised for
serial transplantations at 1 cm diameter.
FACS
Melanoma cells were incubated with 1mM BODIPY aminoacetalde-
hyde (Aldefluor), a fluorescent substrate to ALDH, according
to the manufacturer’s protocol. Cells were also incubated
with phycoerythrin-conjugated anti-human CD133/1(AC133)
antibody (Miltenyi, Bergisch Gladbach, Germany), according to
the manufacturer’s protocol. Allophycocyanin-conjugated anti-hu-
man CD45 antibody was used to exclude bone marrow-derived
cells. Sorting was conducted on a FACSAria (Becton Dickinson)
utilizing FACSDiva software and a purity prioritization algorithm.
FlowJo software (Treestar, Ashland, OR) was used for data analysis.
CD133þ melanoma cells were separated by an AutoMACS Separator
(Miltenyi Biotec, Auburn, CA). The CD133þ population was confirmed
by FACS.
Immunostaining
Paraffin-embedded sections were deparaffinized, rehydrated, and
antigen enhanced with Reaction Buffer (Ventana Medical Systems,
Oro Valley, AZ). ALDH1 antibody (ab52492, Abcam, Cambridge,
MA) was used according to the manufacturer’s instructions. Human-
specific mAb anti-CD45 and anti-CD31 antibodies (Cell Marque,
Rocklin, CA) and mAb anti Ki-67 antibody (Ventana Medical
Systems) were used.
Statistical analysis
Injection sites were scored as positive or negative for tumor, based
on gross observation and subsequent histological confirmation. The
ratio of positive results/total injections for each dose of cells injected
was determined. Using this data, limiting dilution analysis of the
frequency of MICs for each cell population was performed using L-
Calc (Stemsoft, Vancouver, Canada) statistical software. The Spear-
man correlation coefficient was used to assess the association
between variables. A Stratified Cox regression model was used to
assess differences in time to first palpability.
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